We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HR
126
DELISTED
Healthcare Realty Trust Incorporated
HR
$3.1M 0.1%
104,024
– –
WST icon
127
West Pharmaceutical
WST
$24.5B
$2.65M 0.09%
+6,240
New +$2.63M
TECH icon
128
Bio-Techne
TECH
$11.2B
$2.62M 0.08%
21,600
-8,800
-29% -$1.07M
XENE icon
129
Xenon Pharmaceuticals
XENE
$6.02B
$2.58M 0.08%
169,030
– –
XRN
130
Chiron Real Estate Inc
XRN
$511M
$2.57M 0.08%
34,979
– –
STOK icon
131
Stoke Therapeutics
STOK
$1.84B
$2.52M 0.08%
+99,263
New +$2.77M
MLTX icon
132
MoonLake Immunotherapeutics
MLTX
$1.48B
$2.47M 0.08%
250,000
– –
PRGO icon
133
Perrigo
PRGO
$1.48B
$2.42M 0.08%
51,224
– –
HR icon
134
Healthcare Realty
HR
$7.12B
$2.1M 0.07%
70,662
– –
HOLX
135
DELISTED
Hologic
HOLX
$2.09M 0.07%
28,347
-4,217
-13% -$316K
TCRR
136
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.01M 0.06%
235,808
– –
MORF
137
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.98M 0.06%
+35,025
New +$2.12M
CDXS icon
138
Codexis
CDXS
$156M
$1.87M 0.06%
+80,448
New +$1.9M
KALV
139
DELISTED
KalVista Pharmaceuticals
KALV
$1.75M 0.06%
100,000
– –
TCRX icon
140
TScan Therapeutics
TCRX
$47.3M
$1.67M 0.05%
+200,000
New +$1.85M
ENDP
141
DELISTED
Endo International plc
ENDP
$1.6M 0.05%
494,607
-36,963
-7% -$131K
PTGX icon
142
Protagonist Therapeutics
PTGX
$8.51B
$1.53M 0.05%
+86,237
New +$3.68M
BCEL
143
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.43M 0.05%
229,372
-123,052
-35% -$820K
PRAX icon
144
Praxis Precision Medicines
PRAX
$8.52B
$1.39M 0.04%
5,000
– –
ZGNX
145
DELISTED
Zogenix, Inc.
ZGNX
$1.35M 0.04%
88,977
– –
CCXI
146
DELISTED
ChemoCentryx, Inc.
CCXI
$1.34M 0.04%
78,197
– –
FULC icon
147
Fulcrum Therapeutics
FULC
$283M
$1.24M 0.04%
+43,898
New +$832K
DHC
148
Diversified Healthcare Trust
DHC
$2.13B
$1.21M 0.04%
357,720
– –
CYH icon
149
Community Health Systems
CYH
$412M
$1.19M 0.04%
101,535
– –
ITOS
150
DELISTED
iTeos Therapeutics
ITOS
$1.14M 0.04%
+42,362
New +$1.11M
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.